ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

First, select a broad health condition.
32707 results sorted by trial registration date.
Clear all

  • Disrupt PAD+ Study With the Shockwave Medical M5+ Peripheral IVL System

    Prospective, multi-center, single-arm study of the M5+ Peripheral IVL system to treat calcified peripheral arteries.

    Registration number:
    NCT04585763
    Broad health category:
    • Peripheral Arterial Disease
    • Vascular Disease, Peripheral
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • NSW
    • WA
    • Not specified
    Gender:
    • All

  • The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.

    Registration number:
    NCT04585750
    Broad health category:
    • Advanced Solid Tumor
    • Advanced Malignant Neoplasm
    • Metastatic Cancer
    • Metastatic Solid Tumor
    • Lung Cancer
    • Ovarian Cancer
    • Endometrial Cancer
    • Prostate Cancer
    • Colorectal Cancer
    • Breast Cancer
    • Other Cancer
    • Locally Advanced
    • Head and Neck Cancer
    • Gall Bladder Cancer
    • Small Cell Lung Cancer
    • Small Cell Lung Cancer ( SCLC )
    • Small Cell Lung Carcinoma
    • NSCLC
    • NSCLC (Non-small Cell Lung Cancer)
    • SCLC
    • Non-Small Cell Lung Carcinoma
    • Triple Negative Breast Cancer
    • TNBC
    • HER2+ Breast Cancer
    • Non-Small Cell Lung Cancer
    • ER/PR Positive Breast Cancer
    • HER2- Breast Cancer
    • HER2-positive Breast Cancer
    • HER2-negative Breast Cancer
    • ER/PR(+), Her2(-) Breast Cancer
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • NSW
    • QLD
    • SA
    • VIC
    • WA
    • Not specified
    Gender:
    • All

  • FM101 Safety, Tolerability, Efficacy Study in the Patients With Ocular Hypertension

    A PHASE 1/2A, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF FM101 IN PATIENTS WITH OCULAR HYPERTENSION, AND TO ASSESS THE RELATIVE BIOAVAILABILITY OF THE FM101 ORAL TABLET FORMULATION IN HEALTHY PARTICIPANTS

    Registration number:
    NCT04585100
    Broad health category:
    • Ocular Hypertension
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • UNKNOWN
    Recruitment sites:
    • NSW
    • Not specified
    Gender:
    • All

  • Study to Evaluate D-1553 in Subjects With Solid Tumors

    This is a phase 1/2, open label study of D-1553 single agent and combination treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation.

    Registration number:
    NCT04585035
    Broad health category:
    • Solid Tumor, Adult
    • NSCLC
    • CRC
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Active, not recruiting
    Recruitment sites:
    • NSW
    • SA
    • VIC
    • WA
    • Not specified
    Gender:
    • All

  • The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery

    To evaluate the safety and performance of the EVSS in patients with symptomatic peripheral vascular disease from stenosis or occlusion of the femoropopliteal artery

    Registration number:
    NCT04584632
    Broad health category:
    • Peripheral Arterial Disease
    • Vascular Diseases
    • Stenosis
    • Femoropopliteal Stenosis
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • NSW
    • Not specified
    Gender:
    • All

  • A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

    The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of tiragolumab in combination with atezolizumab and chemotherapy in participants with metastatic and early triple-negative breast cancer (TNBC).

    Registration number:
    NCT04584112
    Broad health category:
    • Triple-Negative Breast Cancer
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • QLD
    • WA
    • Not specified
    Gender:
    • All

  • A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)

    This study will evaluate the effect of each dose of MK-3655 versus placebo on the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks. The primary hypothesis of the study is that at least 1 dose of MK-3655 is superior to placebo with respect to the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks.

    Registration number:
    NCT04583423
    Broad health category:
    • Nonalcoholic Steatohepatitis
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Stopped early
    Recruitment sites:
    • NSW
    • SA
    • Not specified
    Gender:
    • All

  • A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19

    This study is a combined Phase 1 and Phase 2 study with IV infusion of NGM621 to evaluate the safety, tolerability, and PK in healthy volunteers (Part 1), and safety, tolerability, PK and efficacy in subjects with confirmed SARS-CoV-2 infection (Part 2).

    Registration number:
    NCT04582318
    Broad health category:
    • SARS-CoV-2 Infection
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Stopped early
    Recruitment sites:
    • Not specified
    Gender:
    • All

  • Study to Evaluate the Safety and Tolerability of EP0042

    A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).

    Registration number:
    NCT04581512
    Broad health category:
    • Acute Myeloid Leukemia
    • Chronic Myelomonocytic Leukemia
    • Myelodysplastic Syndromes
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • WA
    • Not specified
    Gender:
    • All

  • A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

    This open-label, entry-into-human (EIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of RO7283420. Escalating doses of RO7283420 will be administered to participants with Acute Myeloid Leukemia (AML) in order to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D).

    Registration number:
    NCT04580121
    Broad health category:
    • Acute Myeloid Leukemia
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • VIC
    • Not specified
    Gender:
    • All
Tags:
  • Finding clinical trials